JU
JUNS.US Jupiter Neurosciences, Inc. Common Stock
- Market cap
- USD 2.32M
- P/E
- -
- P/B
- 44.71x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is JUNS.US undervalued?
Graham numberThe Graham number of Jupiter Neurosciences, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jupiter Neurosciences, Inc. Common Stock fundamental analysis
No fundamental analysis for Jupiter Neurosciences, Inc. Common Stock yet.
Jupiter Neurosciences, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II …
Full company profileJupiter Neurosciences, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jupiter Neurosciences, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 1.13M | 638K | 233K | 0.00 | 0.00 | 21.8K | 85.8K |
| Gross Profit | - | 1.13M | 638K | 233K | - | - | 17.6K | 70.7K |
| Operating Income | -2.18M | -1.85M | -3.91M | -3.43M | -3.87M | -3.09M | -8.91M | -9.41M |
| EBITDA | -2.73M | -1.64M | -4.09M | -4.22M | -4.56M | -2.19M | -8.58M | -8.99M |
| Net Income | -3.05M | -1.65M | -4.38M | -4.96M | -4.78M | -2.44M | -8.64M | -8.67M |
| EPS | -26 | -14 | -35 | -11 | -11 | -6.36 | -19 | -16 |
| Balance Sheet | ||||||||
| Total Assets | 6.18K | 550K | 667K | 236K | 149K | 6.20M | 5.56M | 3.72M |
| Total Liabilities | 5.02M | 4.26M | 5.85M | 7.38M | 5.95M | 2.03M | 7.40M | 4.08M |
| Shareholders' Equity | -5.02M | -3.71M | -5.18M | -7.14M | -5.80M | 4.17M | -1.83M | -366K |
| Cash & Short-term Investments | 1.28K | 208K | 331K | 64.4K | 28.5K | 3.77M | 3.79M | 1.52M |
| Total Debt | 1.21M | 108K | 651K | 1.90M | 2.25M | 218K | 5.32M | 1.75M |
| Cash Flow | ||||||||
| Operating Cash Flow | -143K | -255K | -1.74M | -1.25M | -481K | -3.91M | -5.41M | -7.45M |
| Capital Expenditure | 0.00 | 0.00 | 4.00 | 4.00 | 3.00 | 4.00 | 4.00 | 0.00 |
| Free Cash Flow | -143K | -255K | -1.74M | -1.25M | -481K | -3.91M | -5.41M | -7.45M |
| Ratios | ||||||||
| ROE | - | - | - | - | - | -58.5% | - | - |
| ROA | -49,323.6% | -300.9% | -656.2% | -2,101.2% | -3,219.3% | -39.3% | -155.4% | -233.2% |
| Net Profit Margin | - | -146.9% | -686.4% | -2,125.2% | - | - | -39,662.8% | -10,108.8% |
| Debt to Equity | - | - | - | - | - | 0.05x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jupiter Neurosciences, Inc. Common Stock dividends
Jupiter Neurosciences, Inc. Common Stock has not paid dividends in the last 7 fiscal years.
Last stock split: 1:75 on Aug 7, 2026.
Who owns Jupiter Neurosciences, Inc. Common Stock
- Insiders 30.64%
- Institutions 3.89%
- Public & others 65.47%
- Shares outstanding 1.32M
- Free float 564K
Top funds holding JUNS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 1.13K | 0.09% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 239.00 | 0.02% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 214.00 | 0.02% | 0.00% | Sep 2026 |
Top institutions holding JUNS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Virtu Financial LLC | 231K | 0.23% | +1,603.43% | Jun 2026 |
| Geode Capital Management, LLC | 156K | 0.16% | -26.25% | Jun 2026 |
| Vanguard Capital Management, LLC | 128K | 0.13% | -64.42% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 84.2K | 0.09% | -4.12% | Jun 2026 |
| Northern Trust Corp | 25.3K | 0.03% | 0.00% | Jun 2026 |
| Vestor Capital Partners | 2.19K | 0.00% | -99.77% | Jun 2026 |
| Midfirst Bank | 1.00K | 0.00% | 0.00% | Jun 2026 |
| Citigroup Inc | 546.00 | 0.00% | 0.00% | Jun 2026 |
| Yorkville Advisors Global, LP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Citadel Advisors Llc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| UBS Group AG | 0.00 | 0.00% | -100.00% | Jun 2026 |
Jupiter Neurosciences, Inc. Common Stock company profile
- Company name
- Jupiter Neurosciences, Inc. Common Stock
- Ticker
- JUNS.US
- Exchange
- USA Stocks
- Listed since
- Dec 3, 2024
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 5
- Fiscal year end
- December
- Address
- 1001 North US Highway 1, Jupiter, FL, United States, 33477
- Phone
- 561 406 6154
- Website
- jupiterneurosciences.com
About Jupiter Neurosciences, Inc. Common Stock
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Jupiter Neurosciences, Inc. Common Stock management
6- Mr. Christer RosenCo-Founder, CEO & Chairman of the Board · born 1953
- Ms. Alison D. Silva MA, MSPresident, COO & Director · born 1979
- Dr. Marshall Hayward Ph.D.Co-Founder, Chief Scientific Officer & Director · born 1956
- Mr. Alexander RosenCo-Founder & Chief Administrative Officer · born 1992
- Mr. Saleem Elmasri CPACFO & Secretary · born 1986
- Dr. Claes Wahlestedt M.D., Ph.D.Co-Founder, Co-Chairman of Scientific Advisory Board & Consulting Chief Medical Officer · born 1959